|
|
Profile
|
Delegates :
Takeshi Takata |
|
Incorporated :
September 7 , 1972 |
Paid in Capital :
90 Million yen |
Employees :
333 人 |
Address :
163 Konaka, Toyama-city TOYAMA
〒939-8183
|
TEL/FAX :
076-429-1865 / |
URL：
https://www.hanshin-group.co.jp/ |
Attachment :
|
Mission/Background :
The Hanshin Group has been in business for about 100 years since it was founded in 1920 as a private company for the purpose of manufacturing glass bottles.
In 2017, the entire group had net sales of 24 billion yen and ranked second in the industry in the manufacture of pharmaceutical containers.
In 2018, the company started a new regenerative medicine business.
In January 2025, we plan to launch a cell culture platform business that doubles the efficiency of cell culture experiments by remotely managing and operating cell culture. |
|
Technology & Business
|
The cell culture platform is a system that allows centralized management of data automatically obtained from IoT-enabled clean benches and incubators on the cloud and AI image diagnosis of cell proliferation status, and is highly anticipated both domestically and internationally.
In the future, we would like to combine this system with a fully automated cell bank and metaverse to create a solution that will be useful as an R&D infrastructure in various fields.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
IoT-enabled equipment
|
Service/Marketing
|
Platform for regenerative medicine cell culture (remote observation and operation possible)
|
To begin sales in January 2025.
|
Cloud services
|
Service/Marketing
|
Platform for regenerative medicine cell culture (remote observation and operation possible)
|
To begin sales in January 2025.
|
Dedicated EC site
|
Service/Marketing
|
Platform for regenerative medicine cell culture (remote observation and operation possible)
|
To begin sales in January 2025.
|
Support for development of regenerative medicine-related products
|
Service/Marketing
|
Platform for regenerative medicine cell culture (remote observation and operation possible)
|
To begin sales in January 2025.
|
|
|
|
|
|
Highlights
|
At last year's BioJapan, where the company exhibited for the first time, approximately 300 people visited the booth over a three-day period. The company also exhibited at the G7 Health Ministers' Meeting held in May of this year, receiving favorable reviews both at home and abroad.
Related patents have been applied for.
|
|
Alliance strategy
|
Preparing an e-commerce site dedicated to regenerative medicine, hoping to form alliances with manufacturers who wish to handle the product.
|
|
|